Article
Oncology
Daniel Groener, Jennifer Wichert, Magdalena Adams, Nicolai Mader, Konrad Klimek, Christina Nguyen Ngoc, Justus Baumgarten, Christian Happel, Philipp Mandel, Felix K. H. Chun, Nikolaos Tselis, Frank Gruenwald, Amir Sabet
Summary: This study aims to assess the change in uptake to reference organs, including the liver, parotid, and salivary glands after radioligand therapy (RLT) with [Lu-177]Lu-PSMA-617 in relation to pretreatment imaging metrics. The results showed that RLT has a significant impact on salivary gland uptake, while the changes in liver uptake are burden-dependent.
Article
Medicine, General & Internal
Oliver Sartor, Johann de Bono, Kim N. Chi, Karim Fizazi, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Luke T. Nordquist, Nitin Vaishampayan, Ghassan El-Haddad, Chandler H. Park, Tomasz M. Beer, Alison Armour, Wendy J. Perez-Contreras, Michelle DeSilvio, Euloge Kpamegan, Germo Gericke, Richard A. Messmann, Michael J. Morris, Bernd J. Krause
Summary: The radioligand therapy with Lu-177-PSMA-617 prolonged both imaging-based progression-free survival and overall survival in patients with PSMA-positive metastatic castration-resistant prostate cancer when added to standard care. Adverse events were more common with Lu-177-PSMA-617 but did not significantly impact quality of life.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Thorsten Derlin, Liam Widjaja, Rudolf A. Werner, Frank M. Bengel
Summary: The study aimed to evaluate the feasibility, additional benefit, and toxicity of extending prostate-specific membrane antigen (PSMA) targeted radioligand therapy in patients with metastatic castration-resistant prostate cancer. The results showed that extending the treatment could achieve additional therapeutic effect with mild toxicity. Therefore, treatment extension is feasible and effective for patients with metastatic castration-resistant prostate cancer.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Article
Oncology
Christoph Henkenberens, Thorsten Derlin, Frank Bengel, Tobias L. Ross, Markus A. Kuczyk, Frank A. Giordano, Gustavo R. Sarria, Leonard Christopher Schmeel, Hans Christiansen, Christoph A. J. von Klot
Summary: PSMA PET-guided RT could be a feasible treatment option for patients with oligometastatic mCRPC in delaying further systemic therapies, as shown in this study with a median bPFS of 12.0 months and a median SST-FS of 15.0 months.
FRONTIERS IN ONCOLOGY
(2021)
Article
Chemistry, Medicinal
Zhihao Zha, Seok Rye Choi, Linlin Li, Ruiyue Zhao, Karl Ploessl, Xinyue Yao, David Alexoff, Lin Zhu, Hank F. Kung
Summary: This study successfully transformed a PSMA-targeting imaging agent into promising radionuclide therapeutic agents using Lu-177 isotope. Both newly developed agents showed excellent PSMA binding affinity and exhibited good tumor uptake and blood clearance in a mouse model. One of the agents also demonstrated an extended blood half-life and longer tumor residence time.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yining Wang, Zijun Chen, Yinjie Zhu, Haitao Zhao, Lianghua Li, Gang Huang, Wei Xue, Ruohua Chen, Jianjun Liu
Summary: The purpose of this study was to assess whether total-body [(68) Ga]Ga-PSMA-11 PET/CT could improve the detection rate compared with conventional [(68) Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer. The results showed that total-body [(68) Ga]Ga-PSMA-11 PET/CT had better objective evaluation in terms of background noise, lesion prominence, liver SD, SNR, and lesion SUVmax compared with conventional [(68) Ga]Ga-PSMA-11 PET/CT. Overall, total-body [(68) Ga]Ga-PSMA-11 PET/CT had a significantly higher detection rate for biochemical recurrent prostate cancer compared to conventional [(68) Ga]Ga-PSMA-11 PET/CT. Rating: 9/10.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Review
Radiology, Nuclear Medicine & Medical Imaging
Swayamjeet Satapathy, Ranjit K. Sahoo, Chandrasekhar Bal
Summary: This study aimed to evaluate the impact of prior taxane chemotherapy on response and survival outcomes in mCRPC patients after [177Lu]Lu-PSMA-RLT. Results showed that taxane-naive patients had significantly better outcomes in terms of biochemical response rate, progression-free survival, and overall survival after [177Lu]Lu-PSMA-RLT. Further trials in the taxane-naive setting are required to confirm these findings.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Review
Oncology
Kanchi Patell, Matthew Kurian, Jorge A. Garcia, Prateek Mendiratta, Pedro C. Barata, Angela Y. Jia, Daniel E. Spratt, Jason R. Brown
Summary: 177Lu-PSMA-617 has emerged as a new frontline treatment option for refractory metastatic castrate resistant prostate cancer. The treatment has shown effectiveness and tolerability in phase III studies, and further research on biomarkers is needed to determine patient response. There is also potential for combination therapy with other prostate cancer treatments in the future.
EXPERT REVIEW OF ANTICANCER THERAPY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Xiaomei Gao, Yongxiang Tang, Minfeng Chen, Jian Li, Hongling Yin, Yu Gan, Xiongbin Zu, Yi Cai, Shuo Hu
Summary: This study compared [Ga-68]Ga-RM26 PET/CT and [Ga-68]Ga-PSMA-617 PET/CT for diagnosing prostate cancer, and found that [Ga-68]Ga-PSMA-617 PET/CT had superior accuracy in detecting clinically significant PCa, while [Ga-68]Ga-RM26 PET/CT showed an advantage for imaging low-risk PCa.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Review
Oncology
Ruizhe Huang, Yizhen Li, Haowen Wu, Boyi Liu, Xuanjun Zhang, Zhongxi Zhang
Summary: The aim of this study was to compare the diagnostic efficacy of Ga-68-PSMA-11 PET/CT and Ga-68-PSMA-11 PET/MRI in patients with biochemically recurrent prostate cancer. A meta-analysis and systematic review were conducted, analyzing 37 studies involving 8409 patients. The results showed that Ga-68-PSMA-11 PET/CT and Ga-68-PSMA-11 PET/MRI had similar detection rates for biochemically recurrent prostate cancer. However, larger prospective studies are needed to confirm these findings.
FRONTIERS IN ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Steffie M. B. Peters, Regina Hofferber, Bastiaan M. Prive, Maarten de Bakker, Martin Gotthardt, Marcel Janssen, Frank de Lange, Constantijn H. J. Muselaers, Niven Mehra, J. Alfred Witjes, Pedro F. Costa, James Nagarajah, Mark W. Konijnenberg, Walter Jentzen
Summary: Predicting absorbed doses based on [Ga-68]Ga-PSMA-PET/CT scans can improve patient selection and individualize treatment in [Lu-177]Lu-PSMA therapy. Results show that PET scans can be used to predict absorbed doses to organs and lesions, aiding in treatment management and potentially increasing therapy personalization.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Oncology
Peter Truckenmueller, Josefine Graef, Michael Scheel, Peter Vajkoczy, David Capper, David Kaul, Christian Furth, Holger Amthauer, Winfried Brenner, Julia Sophie Onken
Summary: This study examines the use of PSMA in high-grade gliomas and finds that only a minority of patients with relapsing HGG qualify for PSMA-directed radioligand therapy. PSMA expression and uptake may serve as a screening tool for patient selection.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Vikas Prasad, Kai Huang, Sonal Prasad, Marcus R. Makowski, Norbert Czech, Winfried Brenner
Summary: This study evaluated the role of interim PSMA PET/CT after the 2nd cycle of RLT for early prediction of overall survival in mCRPC patients undergoing RLT with Lu-177-PSMA. The results showed that PET/CT response evaluation is predictive of overall survival and progression of the disease, while PSA response has limited predictive value.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Daniel Groener, Sina Schneider, Justus Baumgarten, Christian Happel, Konrad Klimek, Nicolai Mader, Christina Nguyen Ngoc, Jennifer Wichert, Philipp Mandel, Nikolaos Tselis, Frank Gruenwald, Amir Sabet
Summary: The study examines the association between quantitative uptake parameters on baseline Ga-68-PSMA-11 PET/CT imaging and lesion response to radioligand therapy in patients with metastatic castration-resistant prostate cancer. The results suggest that baseline PSMA uptake is moderately associated with the clinical response to radioligand therapy. Liver-based uptake thresholds have limited value in predicting refractory lesions.
Article
Radiology, Nuclear Medicine & Medical Imaging
Yuheng Liu, Lianghua Li, Yanyu Qin, Zijun Chen, Haitao Zhao, Xinlu Wang, Ruohua Chen
Summary: The objective of this study was to compare the diagnostic performance and image quality of total-body PET/CT imaging using half-dose of [(68) Ga]Ga-PSMA radiotracer to conventional PET/CT imaging using full dose of [(68) Ga]Ga-PSMA. The results showed that total-body PET/CT with half-dose of [(68) Ga]Ga-PSMA yielded comparable image quality and diagnostic performance to conventional PET/CT, while reducing radiation exposure for the subjects.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Letter
Radiology, Nuclear Medicine & Medical Imaging
Kambiz Rahbar, Hojjat Ahmadzadehfar, Martin Boegemann
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2018)
Article
Radiology, Nuclear Medicine & Medical Imaging
Milka Marinova, Martin Muecke, Lukas Mahlberg, Markus Essler, Henning Cuhls, Lukas Radbruch, Rupert Conrad, Hojjat Ahmadzadehfar
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2018)
Meeting Abstract
Oncology
Kambiz Rahbar, Hojjat Ahmadzadehfar, Clemens Kratochwil, Richard P. Baum, Matthias Schmidt, Andreas Pfestroff, Vikas Prasad, Aelxander Heinzel, Juri Ruf, Maria Eveslage, Martin Boegemann, Wolfgang Fendler, Bernd J. Krause
JOURNAL OF CLINICAL ONCOLOGY
(2017)
Article
Biotechnology & Applied Microbiology
Carsten Meyer, Claus Christian Pieper, Hojjat Ahmadzadehfar, Nina Alexandra Lampe, Eva Maria E. Matuschek, Thomas Adrian Maschke, Simon Jonas Enkirch, Markus Essler, Ulrich Spengler, Hans Heinz Schild
ONCOTARGETS AND THERAPY
(2017)
Article
Oncology
Yuri Tolkach, Heidrun Gevensleben, Ralph Bundschuh, Aydan Koyun, Daniela Huber, Christina Kehrer, Thomas Hecking, Mignon-Denise Keyver-Paik, Christina Kaiser, Hojjat Ahmadzadehfar, Markus Essler, Walther Kuhn, Glen Kristiansen
BREAST CANCER RESEARCH AND TREATMENT
(2018)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Kambiz Rahbar, Matthias Weckesser, Hojjat Ahmadzadehfar, Michael Schaefers, Lars Stegger, Martin Boegemann
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2018)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Hojjat Ahmadzadehfar, Markus Essler
JOURNAL OF NUCLEAR MEDICINE
(2018)
Letter
Radiology, Nuclear Medicine & Medical Imaging
Hojjat Ahmadzadehfar, Markus Essler
Article
Environmental Sciences
Clemens Scholl, Ralph A. Bundschuh, Stefan Hirzebruch, Tim Glanert, Xiao Wei, Stefan Kuerpig, Roland Roedel, Markus Essler, Lena Thomas, Hojjat Ahmadzadehfar
JOURNAL OF RADIOLOGICAL PROTECTION
(2019)
Article
Radiology, Nuclear Medicine & Medical Imaging
Milka Marinova, Martin Muecke, Felix Fischer, Markus Essler, Henning Cuhls, Lukas Radbruch, Shiwa Ghaei, Rupert Conrad, Hojjat Ahmadzadehfar
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2019)
Review
Pharmacology & Pharmacy
Narges Jokar, Majid Assadi, Anna Yordanova, Hojjat Ahmadzadehfar
CURRENT PHARMACEUTICAL DESIGN
(2020)
Review
Pharmacology & Pharmacy
Majid Assadi, Narges Jokar, Mojtaba Ghasemi, Iraj Nabipour, Ali Gholamrezanezhad, Hojjat Ahmadzadehfar
CURRENT PHARMACEUTICAL DESIGN
(2020)
Article
Radiology, Nuclear Medicine & Medical Imaging
Hojjat Ahmadzadehfar, Ralf Matern, Richard P. Baum, Robert Seifert, Katharina Kessel, Martin Boegemann, Clemens Kratochwil, Hendrik Rathke, Harun Ilhan, Hanna Svirydenka, Mike Sathekge, Levent Kabasakal, Anna Yordanova, Francisco Osvaldo Garcia-Perez, Kalevi Kairemo, Masha Maharaj, Diana Paez, Irene Virgolini, Kambiz Rahbar
Summary: The extent of bone metastases negatively correlated with overall survival after RLT, but showed no significant correlation with PSA response rate. Prior therapy with Ra-223 may have a positive impact on overall survival.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Majid Assadi, Seyed Javad Rekabpour, Abdullatif Amini, Habibollah Dadgar, Reza Nemati, Ali Gholamrezanezhad, Iraj Nabipour, Esmail Jafari, Hojjat Ahmadzadehfar
MOLECULAR IMAGING AND RADIONUCLIDE THERAPY
(2021)
Review
Pharmacology & Pharmacy
Natasha Alexander, Reza Vali, Hojjat Ahmadzadehfar, Amer Shammas, Sylvain Baruchel
CURRENT RADIOPHARMACEUTICALS
(2018)
